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Identity 
Other names: EIF2AK1, PKR, p68 kinase, PRKR 
HGNC (Hugo): EIF2AK2 
Location: 2p22.2 
Local order: HEAT repeat containing 5B 
(HEATR5B); coiled-coil domain containing 75 
(CCDC75); Eukaryotic translation initiation factor 
2-alpha kinase 2 (EIF2AK2); sulfotransferase family 
member, cytosolic, 6B, member 1 (SULT6B1); 
ribosomal protein L31 pseudogene 16 (RPL31P16). 
DNA/RNA 
Description 
The EIF2AK2 gene spans approximately 50 kb and 
contains 17 exons.  
The coding sequence initiates in exon 3 (Kuhen et al., 
1996). 
Transcription 
Key Promoter Elements: TATA-less (No TATA Box). 
1. KCS (Kinase Conserved Sequence): Nucleotides -
67 to -81 from the transcriptional start site.  
Required for basal expression utilizing Sp factors. Al o 
required in combination with the ISRE for interferon-
stimulated expression (Kuhen and Samuel, 1997; 
Kuhen et al., 1998; Kuhen and Samuel, 1999; Ward 
and Samuel, 2002). 
2. ISRE (Interferon-stimulated response element): 
Nucleotides -50 to -62 from the transcriptional start 
site. Required for the interferon-inducible expression of 
EIF2AK2. Regulated by the binding of STAT1, STAT2 
and IRF9 (Kuhen and Samuel, 1997; Kuhen and 
Samuel, 1999; Ward and Samuel, 2002; Ward and 
Samuel, 2003). 
3. P53RE (p53 response element):Two p53RE 
domains were identified flanking the ISRE. Acts to 
enhance EIF2AK2 expression following genotoxic 
stress (Yoon et al., 2009). 
Transcripts: 
Three (3) transcripts have been identified based on 
alternate splicing of exon 1 with exon 2 in the 5'UTR. 
No change to the protein is observed with these 
transcripts (Kawakubo et al., 1999). 
One (1) alternately spliced transcript (Tissue: Placenta) 
resulting in the loss of exon 12 (Gerhard et al., 2004). 
One (1) alternately spliced transcript (Tissue: 
Brain/Lung) resulting in the loss of exon 11 (Gerhard et 
al., 2004). 
One (1) transcript (Tissue: Brain) which results from an 
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The stick diagram shows the splicing of the exons that compose PKR as well as confirmed and unconfirmed (suggested by cDNA 
libraries from the Mammalian Gene Collection (MGC) only) splicing products and the length of their resulting protein products. The coding 
sequence for PKR initiates in exon 3 at the 17th nucleotide. The coding sequence of PKR is 1656 base pairs; the individual exons contain 
the following coding nucleotides: exon 3 (1-118); exon 4 (119-240); exon 5 (241-389); exon 6 (390-516); exon 7 (517-593); exon 8 (594-
687); exon 9 (688-722); exon 10 (723-785); exon 11 (786-908); exon 12 (909-1067); exon 13 (1068-1248); exon 14 (1249-1377); exon 15 




The protein product of the EIF2AK2 gene is typically 
referred to as PKR in the literature. 
Description 
EIF2AK2/PKR is a 551 amino acid protein with a 
predicted molecular weight of 62,1 kDa (68-72 kDa in 
SDS-PAGE) and a predicted pI of 8,58. PKR first 
described as an interferon-inducible antiviral kinase 
which phosphorylated eIF2-alpha on Ser 51, is now 
best described as a general stress/inflammatory kinase 
which phosphorylates an increasing list of substrates 
which includes eIF2-alpha (Colthurst et al., 1987), p53 
(Cuddihy et al., 1999), B56-alpha (Xu and Williams, 
2000), cyclin dependent kinase (CDK)-1 (Yoon et al.,










The double-stranded RNA dependent kinase (PKR) 
was initially identified as an innate immune anti-viral 
protein approximately 35 years ago (Roberts et al., 
1976b; Roberts et al., 1976a).  
Since then PKR has been linked to normal cell growth 
and differentiation, inflammation, cytokine signaling 
and apoptosis (Garcia et al., 2006). Altered PKR 
activity has been shown to play a role in 
neurodegenerative diseases (Alzheimer's, Huntington's 
and Parkinson's) and cancer (Peel et al., 2001; Peel and 
Bredesen, 2003; Onuki et al., 2004; Peel, 2004; Bando 
et al., 2005; Eley et al., 2009).  
PKR belongs to the eIF2α kinase family which also 
includes PKR-like endoplasmic reticulum kinase 
(PERK), general amino acid control of gene 
expression, non-derepressing 2 (GCN2) and heme-
regulated kinase (HRI).  
Whereas the activation of PERK, GCN2 and HRI are in 
response to more specific stresses; PKR is activated in 
response to diverse stress signals (Shi et al., 1998; 
Berlanga et al., 1999; Williams, 1999; Chen, 2007). 
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The primary amino acid sequence of PKR. The alternate exons to which the individual amino acids belong are indicated by shading. 
Translation of PKR initiates in exon 3 and terminates in exon 17. 
 
The primary protein structure for PKR. Key domains of the protein and the amino acids that compose them are shown, as are the key 
phosphorylation site(s) which are required for kinase activity (T451) (Romano et al., 1998; Zhang et al., 2001) or enhance kinase activity 
(Y101, Y162, S242, T255, T258, Y293 and T446) (Romano et al., 1998; Alisi et al., 2005; Su et al., 2006). 
 
As the first known substrate of PKR was eIF2α, much 
of the research involving PKR has centered on its 
ability to regulate translation under varying conditions. 
Within the past ten years, PKR has been shown to play 
a significant role in signaling pathways involved in 
other cellular process such as cell proliferation, 
differentiation, metabolism, DNA repair and apoptosis 
(Garcia et al., 2006). 
Among the targets that PKR has been demonstrated to 
phosphorylate or directly influence the phosphorylation 
of are: p53, signal transducer and activators of 
transcription factors STAT1 and STAT3, inhibitor κB 
kinase (IKK)-β, inhibitor κB (IκB)-β, the B56α 
regulatory subunit of PP2A, and RNA helicase (Garcia 
et al., 2006; Sadler et al., 2009). In addition to these 
targets, PKR has been shown to influence signaling 
through the phosphatidylinositol-3 kinase (PI3K)/AKT 
pathway and transcription factors NF-κB, C/EBPα, 
C/EBPβ and ATF3. PKR also influences signaling 
through the MAPK signal transduction pathways. PKR 
activity is required for activation of p38-MAPK and 
JNK in response to particular stresses, and signaling 
through these MAPKs is defective in PKR-/- cells. The 
PKR dependent mechanism involved in p38MAPKand 
JNK activation may involve the interaction of PKR 
with ASK1 or MKK6. Additionally, inhibition of 
protein synthesis may reduce the level of negative 
regulators of these kinases (Garcia et al., 2006). 
Activation 
PKR activation was originally thought to occur only in 
the presence of double-stranded RNA (ex. viral 
infection). Over time increasing evidence has indicated 
that PKR activation is induced by cytotoxic cytokines 
(tumor necrosis factor (TNF)-α and IFNγ), growth 
factor deprivation, oxidative stress and DNA damage 
(Garcia et al., 2006). 
PKR is potentially serine/threonine and tyrosine 
phosphorylated on 105 different sites (54 Ser, 33 Thr 
and 18 Tyr), including 15 suspected 
autophosphorylation sites. Of these, only 8 sites have 
so far been identified, and their significance to PKR 
activation determined. Phosphorylation of Thr451 in 
the catalytic domain of PKR is required for minimal 
kinase activity (Romano et al., 1998; Zhang et al.,
2001). An additional phosphorylation of PKR on 
Thr446 serves to augment PKR activity (Romano et al., 
1998; Alisi et al., 2005). 
In addition to Thr446/451 phosphorylation, 
phosphorylation on three key tyrosine residues 
(Tyr101/162/293) is also required for maximal PKR 
activity (Su et al., 2006). In cell culture, PKR appears 
to be constitutively tyrosine phosphorylated, but the 
exact tyrosine sites that are phosphorylated have not 
been determined nor has the kinase(s) responsible for 
these phosphorylations. PKR kinase assays using wild-
type eIF2α or mutants Ser51Thr or Ser51Tyr revealed  
that PKR could phosphorylate the residue at position 51 
equally (Lu et al., 1999). One suggestion is that PKR 
possess tyrosine kinase ability and is able to 
autophosphorylate (Lu et al., 1999). This is supported 
by the finding that a catalytically-inactive mutant 
(K296R) of PKR is not tyrosine phosphorylated in vitro 
and in vivo (Su et al., 2006). More recent, findings 
indicate PKR is associated with JAK1 and TYK2 
kinases in resting cells. Following interferon 
stimulation, exogenously expressed JAK1 and TYK2 
were demonstrated to phosphorylate Tyr101 and 
Tyr293 (Su et al., 2007). Similarly the catalytic mutant 
of PKR was also tyrosine phosphorylated by the JAK 
kinases. As tyrosine phosphorylation of PKR in 
response to dsRNA is not affected in cells deficient n 
JAK kinases, other tyrosine kinases may potentially 
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phosphorylate these sites in response to different 
stresses (Su et al., 2007).  
The role of PKR as a non-receptor tyrosine kinase 
remains controversial. 
eIF2α 
In order to properly initiate translation, the eIF2 
complex must hydrolyze GTP to GDP in the presence 
of Met-tRNA and the 40S ribosomal subunit.  
Efficient recycling of the complex then involves the 
removal of GDP and the re-loading of GTP to the eIF2 
complex; a process carried-out by the GTP-exchange 
factor, eIF2B (Kimball et al., 1998). Phosphorylation of 
the eIF2α subunit turns the eIF2 complex into a 
competitive inhibitor. Those eIF2 complexes 
containing phosphorylated eIF2α demonstrate 
increased affinity for eIF2B and associate, blocking the 
eIF2 complex in the GDP bound state (Krishnamoorthy 
et al., 2001). As the eIF2 complex is in excess of 
eIF2B, a small amount of phosphorylated eIF2α can 
result in a shut-off of general translation (Kimball et 
al., 1998; Sudhakar et al., 2000; Krishnamoorthy et al., 
2001; Nika et al., 2001; Wek et al., 2006). The 
inhibition of general translation is mainly thought to be 
pro-apoptotic, but recent evidence has suggested that 
this may be a cellular defense mechanism against 
stresses (Wek et al., 2006). 
Phosphorylation of eIF2α results in a shut-off of 
general translation but at the same time allows for 
efficient translation of uORFs in particular mRNAs, 
such as ATF4, due to their 5' structure; or through what 
is termed internal ribosome entry site (IRES)-mediated 
translation (Fernandez et al., 2002; Gerlitz et al., 2002; 
Yaman et al., 2003). Many of these mRNAs encode 
proteins involved in the stress response (Koschmieder 
et al., 2007; van den Beucken et al., 2007; Lee et al., 
2009). Short-term inhibition of general translation 
through eIF2α phosphorylation may in fact be pro-
survival by allowing for cellular repair following a 
particular stress (Donze et al., 2004). 
p53 
PKR was shown to phosphorylate cytoplasmic p53 on 
Ser392 enhancing p53 tetramer stability and 
transcriptional activation of p53 targeted genes 
(Sakaguchi et al., 1997; Cuddihy et al., 1999; Keller et 
al., 2001). Among these are p21-Cip1, BAX, PUMA 
and several pro-caspases. The implications of this 
phosphorylation are a PKR-mediated cell cycle arrest 
and induction of apoptosis. Inhibition of constitutive 
PKR activity in several acute leukemia cells lines with 
a small molecule inhibitor has been observed to lead to 
p53 degradation (Unpublished results). Although the
exact mechanism for p53 degradation has not been 
determined, it likely involves the activation of AKT, 
whose phosphorylation and activity are observed to 
increase, and AKT effects upon MDM2 (Blalock et al.,
2009). Additionally, the cellular PKR activator 
RAX/PACT was demonstrated to result in increased 
cellular levels of p53, p53 transcriptional activity and 
growth arrest in a PKR dependent manner (Bennett et 
al., 2012). Expression of a siRNA to RAX, which 
blocks the ability of most stresses to activate PKR, 
resulted in the decreased expression of several p53 
regulated genes such as p21Cip1and PUMA and lower 
constitutive levels of p53. RAX resulted in the 
SUMOylation of p53 in a PKR independent manner, 
through direct interaction and activation of the E2 
ligase Ubc9 (Bennett et al., 2012). 
NF-κB 
PKR association with inhibitor κB kinase (IKK) was 
demonstrated to induce NF-κB nuclear translocation 
and transcriptional activity (Gil et al., 2000; Zamnian-
Daryoush, et al., 2000). While initially PKR kinase 
activity was implicated in the activation of NF-κB, 
PKR catalytic activity is not a requirement. Truncated 
forms of PKR consisting of the amino terminus were 
shown to associate with the IKK complex and stimulate 
IκBβ phosphorylation (Bonnet et al., 2000; Bonnet et 
al., 2006). Later, Donze et al. showed that PKR 
irregardless of catalytic activity could induce NF-κB 
activation and the synthesis of some NF-κB dependent 
transcripts, but NF-κB activity and transcription of 
other NF-κB dependent genes was greatly potentiated 
when PKR kinase activity remained intact (Donze et 
al., 2004). These data suggest that both PKR 
association with IKK and PKR catalytic activity are 
important for PKR mediated effects on NF-κB. To this 
end the current understanding is that PKR activity is 
required for the full effects of PKR on NF-κB, although 
whether PKR catalytic activity influences NF-κB 
activation at the point of IκB phosphorylation and 
release or at later points, has not been sorted-out. 
STATs 
PKR has also been demonstrated to affect the 
transactivation of STATs 1 and 3 (Karehed et al., 
2007). STAT1 activity is enhanced by phosphorylation 
on Ser727. Phosphorylation of this site is defectiv in 
PKR-/- fibroblasts resulting in a decrease of STAT1 
transactivation (Ramana et al., 2000). PKR kinase 
activity is not necessary for PKR effects on STAT1 
(Wong et al., 1997); instead, PKR associates through 
its NH2-terminus with STAT1, which apparently 
enhances mitogen activated protein kinase (MAPK)-
mediated phosphorylation of STAT1 on Ser727 (Deb et 
al., 2001). Similar to STAT1, PKR has also been 
demonstrated to be required for proper phosphorylation 
and transactivation of STAT3. Like STAT1, PKR 
effects were mediated through MAPK-dependent 
phosphorylation of STAT3 (Deb et al., 2001). In the 
absence of PKR, activation of STAT3 by platelet 
derived growth factor (PDGF) is impaired (Deb et al.,
2001). 
PP2A 
PKR was shown in a yeast-two hybrid system to 
associate with B56α in a manner dependent on PKR 
catalytic activity.  
PKR phosphorylated B56α at multiple sites in vitro 
(among these Ser28) leading to enhanced PP2A activity 
(Xu and Williams, 2000).  






Atlas Genet Cytogenet Oncol Haematol. 2012; 16(9)  605 
The enhancement of PP2A activity via PKR 
phosphorylation of B56α resulted in decreased 
phosphorylation of eIF4E and a lower rate of 
translation. More recently additional effects of PKR on 
PP2A activity have been observed. The lymphocytic 
leukemia cell line REH contains both elevated levels of 
active PKR and a BCL2 targeted phosphatase activity. 
PKR was shown to phosphorylate B56α on Ser28 in 
REH cells which led to PP2A targeting to the 
mitochondria and dephosphorylation of BCL2 (Ruvolo 
et al., 2008). PKR activity was also shown to stabilize 
B56α, but this stabilization was not dependent on Ser28 
phosphorylation but instead on eIF2α phosphorylation. 
CDK1 
Yoon et al. demonstrated that during genotoxic stres  
PKR is responsible for phosphorylating Cdc2 (CDK1) 
on Tyr4. Phosphorylation at this site was shown to 
result in ubiquitination and proteosomal degradation of 
Cdc2 thus resulting in a G2 arrest (Yoon et al., 2010). 
IRS-1 
PKR was found to link chronic inflammatory responses 
to metabolic signaling through the phosphorylation of 
the insulin response substrate (IRS)-1 on Ser312.  
Phosphorylation at this site inhibits the phosphorylation 
of key tyrosine residues required for insulin induced 
signaling (Nakamura et al., 2010; Yang et al., 2010a). 
Homology 
H. sapiens: (100%) 
P. troglodytes: (98%) 
C. lupus: (55%) 
B. taurus: (62%) 
M. musculus: (58%) 
R. norvegicus: (51%) 
G. gallus: (39%) 
D. rerio: (30%) 
Mutations 
Note 
Although the 2p22-p21 locus is often rearranged in 
leukemia no data supports these alterations affecting 
EIF2AK2.  
A single nucleotide mutation was documented in a 
single pediatric T-ALL patient.  
The mutation occurred in the first double-stranded 
RNA binding domain and resulted in a protein that 
could not be activated by polyI:C (Murad et al., 2005). 
In a murine model of chronic lymphocytic leukemia 
(CLL), a rearrangement in one locus of EIF2AK2 
results in the deletion of 550 nucleotides and the 
production of a truncated protein with dominant-




- DNA: nt50 (A to G); Protein: aa17 (Tyr to Cys); 
Source: Pediatric T-ALL; Influence on pathology not 
determined. 
- DNA: nt1872 (C to G); Protein: aa439 (Leu to Val); 
Source: adenocarcinoma; Influence on pathology not 
determined.  
Single Nucleotide Polymorphisms 
SNP analysis revealed V428E (T1840A; source 
unknown), I506V (A2073G; source unknown). 
Additional polymorphisms (1084) identified in the 
genomic sequence in the locus of EIF2AK2 can be 
found at PheGenI. 
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Post-translational modification. (Taylor et al., 2001)a; (Su et al., 2006)b; (Romano et al., 1998)c; (Alisi et al., 2005)d; (Zhang et al., 
2001)e; (Olsen et al., 2010)f; (Dephoure et al., 2008)g; (CST Curation Set Data available from Phosphosite Plus at 
http://www.phosphosite.org)h; (Christensen et al., 2010)i; (Kim et al., 2011)j; (Wagner et al., 2011)k. 
 
Implicated in 
Myelodysplastic syndromes (MDS) 
Note 
The presence of phospho-T451 PKR (p-T451 PKR) is 
slightly elevated in the cytoplasm of bone-marrow 
mononuclear cells (BMMC) from low-risk/INT-1 MDS 
patients. In contrast, BMMCs from INT-2/high-risk 
MDS patients show an enhanced presence of p-T451 
PKR with primarily nuclear localization (Follo et al., 
2008).  
Inhibition of PKR kinase activity or expression 
reverses the suppressive effects of IFNγ and TNFα on 
colony formation from CD34+ hematopoietic 
progenitors and increases hematopoietic colony 
formation from human isolated MDS progenitors 
(Sharma et al., 2011). 
Loss of PKR expression is observed in 5q- and 5q:31-
33 myelodysplasias (Green et al., 1999; Giagounidis et 
al., 2004). 
Disease 
Bone marrow failure disorder. 
Prognosis 
The presence of p-T451 PKR in the cytoplasm is 
associated with low-risk disease. 
The presence of p-T451 PKR in the nucleus is 
associated with high-risk disease and thus an enhanced 
probability of progression to acute myelogenous 
leukemia (AML). 
Loss of PKR in 5q- and 5q32-33 myelodysplasias is  
associated with low-risk disease, while loss of PKR in 
5q31 myelodysplasias with complex cytogenetics is 
associated with high-risk disease. 
Oncogenesis 
Progression to acute myelogenous leukemia. 
Fanconi anemia (FA) 
Note 
PKR activity is constitutively elevated in bone marrow 
cells from Fanconi anemia patients and cells lines and
contributes to the hypersensitivity of these cells to 
TNFα and IFNγ (Pang et al., 2001; Zhang et al., 2004).  
Inhibition of PKR activity by either expressing a 
dominant negative PKR kinase or a dominant-negative 
form of the cellular PKR activator RAX/PACT (S18A) 
reduces apoptosis and sensitivity to TNFα and IFNγ 
(Pang et al., 2001; Bennett et al., 2006). 
Disease 




Progression to acute myelogenous leukemia. 
Acute myelogenous leukemia (AML) 
Note 
PKR is overexpressed in blasts from AML patients, and
is a functional kinase (Basu et al., 1997). AML deriv d 
cell lines contain elevated levels of p-T451 PKR as 
compared to control peripheral blood lymphocytes 
(Blalock et al., 2009).  
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AML cell lines were highly dependent on PKR activity 
for cell maintenance as treatment of the cells with the 
commercial PKR inhibitor resulted in cell cycle arrest 
and cell death (Blalock et al., 2009). 
Disease 




Contributes to cancer cell maintenance. 
Acute lymphocytic leukemia (ALL) 
Note 
PKR is overexpressed in blasts from ALL patients, and
is a functional kinase (Basu et al., 1997).  
T-ALL derived cell lines contain elevated levels of p-
T451 PKR as compared to control peripheral blood 
lymphocytes (Blalock et al., 2009).  
T-ALL cell lines were highly dependent on PKR 
activity for cell maintenance as treatment of the cells 
with the commercial PKR inhibitor resulted in cell 
cycle arrest (Blalock et al., 2009).  
A somatic point mutation was detected in the coding 
region of dsRNA-binding domain I (coding nucleotide 
50 (A to G); amino acid Y17C) of PKR in a patient 
with T-ALL.  
Although activation of the mutant PKR kinase by 
polyI:C was impaired, the exact role of this mutation n 
the T-ALL was not determined (Murad et al., 2005). 
Disease 




Somatic point mutation in the coding region of dsRNA-
binding domain I (coding nucleotide 50 (A to G); 
amino acid Y17C); Source: T-ALL. 
Oncogenesis 
Contributes to cancer cell maintenance. 
Chronic lymphocytic leukemia (CLL) 
Note 
PKR mRNA is underexpressed in CLL as compared to 
controls, and the kinase is inactive due to the presence 
of a soluble cellular inhibitor (Basu et al., 1997; Hii et 
al., 2004). 
Disease 





Elevated phospho-T446 PKR and/or p-S51 eIF2α were 
associated with longer median survival in patients wi h 
non-small cell lung cancer (NSCLC). Combinations of 
p-PKR/PKR expression or p-eIF2α/PKR expression 
were valuable prognostic markers for survival (Pataer 
et al., 2010; He et al., 2011). Lower levels of PKR 
expression though correlated with aggressive tumor 
behavior, increased lymph node metastasis and shorter 
survival in the patients (Pataer et al., 2010). 
In contrast to NSCLC, a high level of PKR expression 
was associated with shorter overall survival in patients 
with small-size lung adenocarcinomas (Roh et al., 
2005). 
Disease 
Cancer; Non-small cell lung cancer (NSCLC) and 
small cell adenocarcinoma of the lung. 
Prognosis 
PKR expression and activation as determined by 
immunocytochemistry (p-T446 PKR) are associated 
with a positive prognosis in NSCLC. 
PKR expression in small-size lung adenocarcinomas is 
associated with a poor prognosis. 
Oncogenesis 
Low levels of PKR expression favor aggressive 
behavior and metastasis in NSCLC. 
Breast carcinoma 
Note 
Breast carcinoma cells contain elevated PKR protein 
and activity (7-40 fold) as compared to controls (Kim 
et al., 2000; Nussbaum et al., 2003). Stimulation of the 
PKR promoter ISRE is responsible for enhanced PKR 
expression (Nussbaum et al., 2003). 
Elevated PKR activity is further linked to macrophage-
migration inhibitory factor (MIF) expression which 
favors breast cancer cell growth, but also sensitize  
breast cancer cells to PKR-mediated killing as the 
system is already primed (Armstrong et al., 2008; 
Pervin et al., 2008). 
PKR may assist in the therapeutic response of 
5'Florourocil (5'FU) in p53-null breast cancer (Garci  










Elevated PKR expression and activity are associated 
with progressive transformation from normal mucosa to 
adenoma and colon carcinoma (Kim et al., 2002). 
The activation state of PKR also influences the drug 
sensitivity of colon cancer cells (Yoon et al., 2009; 
Yang et al., 2010b; Garcia et al., 2011). 
Disease 
Cancer; colon adenoma and colon carcinoma. 






Atlas Genet Cytogenet Oncol Haematol. 2012; 16(9)  608 
Prognosis 
Unknown; associated with progressive transformation 
and drug-sensitivity. 
Oncogenesis 
Progressive transformation to adenomas or carcinomas. 
Melanoma 
Note 
Melanomas contain elevated levels of PKR protein, p-
S51 eIF2α and PKR activity as compared to controls 
(Kim et al., 2002).  
PKR was highly expressed in melanoma lymph node 
metastasis (Kim et al., 2002).  
Knock-down of PKR mRNA and protein in B16-F10 
melanoma tumor cells using shRNA led to decreased 
metastatic nodes in mice (Delgado Andre and De 
Lucca, 2007). 
Disease 
Cancer; skin (melanoma). 
Prognosis 
Elevated PKR activity associated with disease 
progression and metastasis. 
Oncogenesis 




PKR is overexpressed in 90% of thyroid cancers, and 
its expression is higher in papillary versus nonpapillary 
carcinoma.  
Elevated PKR expression was associated with vascular 
invasion and satellite tumor nodules. PKR expression 
was linked to a low proliferative activity of the tumor 






Increased invasiveness and satellite tumor formation. 
Pancreatic cancer 
Note 
PKR is upregulated during interferon treatment of 
pancreatic cancer where lower PKR expression 
predicted a shorter anti-cancer response and length of 




Enhanced expression is associated with a favorable 






Levels of phosphorylated forms of PKR and eIF2α 
were elevated in the rectus abdominus muscle of 
oesophago-gastric cancer patients as compared to 




Poor; Phospho-PKR and Phospho-eIF2α are associated 
with muscle wasting. 
Rectal carcinoma 
Note 
PKR protein expression is associated with smaller sized 
tumors, a lower relapse rate and greater 5-year disease-
free and overall survival (Kwon et al., 2005). 
Disease 
Cancer; lymph node negative rectal carcinoma. 
Prognosis 
Favorable; PKR expression is associated with a lower 




Hepatocellular carcinoma (HCC) 
Note 
PKR mRNA and protein are overexpressed and PKR 
kinase activity enhanced in hepatocellular carcinoma 
(Hiasa et al., 2003; Alisi et al., 2005). PKR protein 
levels were observed to increase in bile duct tissue 
during progression to carcinoma, and this increase was 
associated with duct inflammation and duct cell 
proliferation (Terada et al., 2000b).  
Increased PKR expression was associated with both 
chronic hepatitis and HCC (Shimada et al., 1998). 
Importantly, elevated PKR expression is associated 
with better differentiated HCC and cholangiocarcinoma 
(Shimada et al., 1998; Terada et al., 2000b). 
The core protein of hepatitis C virus (HCV), a major 
contributor to HCC, was seen to bind to and activate 
PKR (pT446) in HCC cells and tissue (Delhem et al., 
2001; Alisi et al., 2005).  
In contrast, hepatitis B virus infected HCC liver tissue 
showed decreased PKR expression as determined by 
real-time PCR and immunohistochemistry and no 
association between the status of tumor differentiation 
was observed (Chen et al., 2004). 
Disease 
Cancer; hepatocellular carcinoma (HCC) HCV-
associated HCC, HBV-associated HCC. 
Oncogenesis 
Expression increases with progression toward HCC but 
is associated with better differentiated tumors (except 
in HBV-associated HCC). 
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Alzheimer's disease 
Note 
Phospho-PKR accumulates in the nuclei of AD brain 
tissue (Onuki et al., 2004).  
Neurons from AD patient brains contain elevated levels 
of p-T446 and/or T451 PKR, and p-S51 eIF2α (Peel 
and Bredesen, 2003; Suen et al., 2003) and treatment of 
cell lines with Aβ peptide results in PKR activation, 
eIF2α phosphorylation and the co-localization of p-
PKR with Redd1 and FADD in the nucleus (Suen et al., 
2003; Morel et al., 2009b; Couturier et al., 2010a). 
Phospho-PKR is associated with phospho-Tau and 
phospho-p38 in AD brain (Peel and Bredesen, 2003).  
Inhibition of PKR attenuates inflammation as well as 
TNFα, IL-1α, IL-1β, IL-6 expression and apoptosis 
stimulated by Aβ peptide (Couturier et al., 2010b; 
Couturier et al., 2011). 
Elevated levels of p-PKR, p-eIF2α and secretion of 
TNFα, IL-1α, IL-1β and IL-6 are observed in peripheral 
blood mononuclear cells from AD patients (Morel et 




The presence of elevated p-PKR in brain neuronal 
tissue is an indicator of cellular stress and degenration. 
Possible disease indicator. 
An EIF2AK2 SNP (C/T; rs2254958) at position 250 in 
the 5'UTR was found to be associated with Alzheimer's 
disease (Bullido et al., 2008). 
Cytogenetics 
Alzheimer's associated EIF2AK2 SNP (C/T; 
rs2254958). 
Parkinson's disease (PD) 
Note 
Hippocampal neurons from PD patients contain 








PKR binds CAG repeats in mutated Huntington 
transcripts.  
Affected Huntington tissues contain elevated levels of 
p-PKR (active) with a particular increase in the nuclei 






Creutzfeldt-Jakob disease (CJD) 
Note 
Neuronal tissue (frontal, occipital, temporal cortex, 
striatum and cerebellum) from CJD patients contained 
elevated levels of p-T451 PKR localized exclusively to 
the nucleus.  
The levels of p-T451 PKR were associated with 
apoptosis, spongiosis, astrocytosis and disease severity 




The levels of p-T451 PKR are associated with disease 
severity in CJD patients. 
Amyotrophic lateral sclerosis (ALS) 
Note 
The presence of p-T451 PKR increases in spinal cord
tissue from ALS patients 2600% (cytosolic) and 3300% 
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